MarketPulse

Wegovy

11 articles
BenzingaBenzinga··Vandana Singh

Medicare to Cover Wegovy at $50/Month Starting 2026 as GLP-1 Market Expands

CMS launches Medicare GLP-1 Bridge program July 2026, offering Novo Nordisk's Wegovy at $50 monthly copay. Amazon Pharmacy expands oral Ozempic access.
AMZNNVOOzempicWegovy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Novo Nordisk Showcases Obesity Portfolio at European Congress With Wegovy Data, CagriSema Focus

Novo Nordisk will present 52 abstracts on Wegovy and experimental CagriSema at European obesity congress, highlighting cardiovascular benefits and women's health data.
NVOclinical dataweight loss
The Motley FoolThe Motley Fool··Adam Spatacco

Novo Nordisk's 72% Crash: Generational Buying Opportunity or Dangerous Trap?

Novo Nordisk's 72% crash from peaks sparks debate: value trap or buying opportunity amid GLP-1 market competition from Eli Lilly.
LLYNVOVKTXvaluation compressionmarket opportunity
The Motley FoolThe Motley Fool··Justin Pope

Eli Lilly's FDA-Approved Obesity Pill Could Upend Novo Nordisk's Market Dominance

Eli Lilly's new GLP-1 pill Foundayo launches April 6 with fewer restrictions than competitors. Pipeline drug retatrutide shows superior weight loss, threatening Novo Nordisk's obesity market leadership.
LLYNVOFDA approvalGLP-1 drugs
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Novo Nordisk's Subscription Model Could Unlock Massive Obesity Market Despite Lilly Competition

Novo Nordisk launches tiered subscription pricing for Wegovy to expand obesity drug access. Stock trades at attractive 11x forward earnings amid market penetration opportunity.
LLYNVOGLP-1 drugsweight loss medications
BenzingaBenzinga··Vandana Singh

India's Generic Semaglutide Flood Slashes Ozempic Costs by 70%, Reshaping Global Obesity Market

Over 40 Indian pharma companies launched generic semaglutide after patent expiration, pricing treatments 70% below Novo Nordisk's originals. Market expansion planned globally.
NVOHIMSRDYweight loss drugsobesity market
The Motley FoolThe Motley Fool··Geoffrey Seiler

Hims & Hers Surges 40% on Novo Nordisk Deal, But Valuation Concerns Linger

Hims & Hers surges 40% after Novo Nordisk partnership resolves litigation, enabling authorized distribution of Wegovy and Ozempic. Stock trades under 20x forward P/E.
NVOHIMSGLP-1 drugstelemedicine
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

GLP-1 Glory or Diversified Dividend? Novo Nordisk vs. Amgen in Weight Loss Race

Novo Nordisk leads GLP-1 market but faces Eli Lilly competition; Amgen's MariTide offers differentiated approach with less portfolio risk.
AMGNLLYNVOclinical trialsmarket share
BenzingaBenzinga··Vandana Singh

Novo Nordisk Cuts GLP-1 Drug Prices 50% Amid Clinical Setbacks

Novo Nordisk cuts GLP-1 drug prices 50% to $675/month starting 2027 amid clinical setbacks and competitive pressure from rivals like Eli Lilly.
LLYNVOclinical trialprice reduction
Investing.comInvesting.com··Itai Smidt

Novo Nordisk Reassesses Growth Outlook Following CagriSema Trial Setback

Novo Nordisk stock drops 15.9% after CagriSema obesity drug fails trial versus competitor tirzepatide, signaling intensifying competition in the GLP-1 market despite Wegovy's strength.
LLYNVOGLP-1 drugsWegovy
The Motley FoolThe Motley Fool··Rich Smith

Novo Nordisk Stock Pullback Creates Entry Point for Long-Term GLP-1 Investors

Novo Nordisk stock down 67% offers entry point for long-term investors. Strong GLP-1 market position, attractive valuation metrics, and growth potential despite upcoming competition.
LLYNVOstock valuationdividend stocks